PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA
Fourth major clinical trial to select PharmAla Biotech as supplier in Australia VANCOUVER, British Columbia,…
Month: April 2023
PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA
Fourth major clinical trial to select PharmAla Biotech as supplier in Australia VANCOUVER, British Columbia,…
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
– Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid…
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
– Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid…
Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)
Preclinical data from LBIO-115 exon 51 program demonstrate superior levels of exon-skipping that result in…
Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)
Preclinical data from LBIO-115 exon 51 program demonstrate superior levels of exon-skipping that result in…
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
WARREN, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company”…
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
WARREN, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company”…
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study…
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study…
Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress
Further follow-up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research…
Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress
Further follow-up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research…
Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research
RESEARCH TRIANGLE PARK, N.C., April 20, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research
RESEARCH TRIANGLE PARK, N.C., April 20, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Nusano Co-Founder Dr. Howard Lewin to Participate in Truist Securities Virtual Radiopharmaceuticals Event
NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) — Nusano, Inc., a company reshaping the production…
Nusano Co-Founder Dr. Howard Lewin to Participate in Truist Securities Virtual Radiopharmaceuticals Event
NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) — Nusano, Inc., a company reshaping the production…
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
First patient dose in the Phase 1/2 clinical trial expected in mid-2023 BOSTON, April 20,…
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
First patient dose in the Phase 1/2 clinical trial expected in mid-2023 BOSTON, April 20,…
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate…
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate…